Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. St Jude Medical ( STJ) pushed the Health Services industry lower today making it today's featured Health Services laggard. The industry as a whole closed the day up 0.5%. By the end of trading, St Jude Medical fell 82 cents (-2%) to $40.61 on average volume. Throughout the day, 3.8 million shares of St Jude Medical exchanged hands as compared to its average daily volume of 3.1 million shares. The stock ranged in price between $40.38-$41.65 after having opened the day at $41.56 as compared to the previous trading day's close of $41.43. Other companies within the Health Services industry that declined today were: Stereotaxis ( STXS), down 17.6%, Strategic Diagnostics ( SDIX), down 10.8%, Hooper Holmes ( HH), down 8.3%, and Spherix ( SPEX), down 6.3%.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
St. Jude Medical, Inc. develops, manufactures, and distributes cardiovascular and implantable neurostimulation medical devices worldwide. It operates in two divisions, Cardiovascular and Ablation Technologies, and Implantable Electronic Systems. St Jude Medical has a market cap of $11.98 billion and is part of the health care sector. The company has a P/E ratio of 17.7, equal to the S&P 500 P/E ratio of 17.7. Shares are up 15.3% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate St Jude Medical a buy, no analysts rate it a sell, and 14 rate it a hold. TheStreet Ratings rates St Jude Medical as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.